The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | |||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | ||||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | FIGI | (to the nearest dollar) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| VANGUARD INDEX FDS | S&P 500 ETF SHS | 922908363 | 36,211,589 | 68,413 | SH | SOLE | 68,413 | 0 | 0 | |||
| VANGUARD BD INDEX FDS TOTAL BND MRKT | TOTAL BND MRKT | 921937835 | 41,523,061 | 552,830 | SH | SOLE | 552,830 | 0 | 0 | |||
| VANGUARD INTL EQUITY INDEX F | TT WRLD ST ETF | 922042742 | 40,155,879 | 335,471 | SH | SOLE | 335,471 | 0 | 0 | |||
| PYXIS ONCOLOGY INC | COMMON STOCK | 747324101 | 178,843 | 48,731 | SH | SOLE | 48,731 | 0 | 0 | |||
| NKGEN BIOTECH INC | COM | 65488A101 | 207,900 | 550,000 | SH | SOLE | 550,000 | 0 | 0 | |||